Overview

North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the NOSE Study is to carefully examine the efficacy and safety of 3 nasal sprays (bevacizumab, estriol, and tranexamic acid), compared to placebo, for the treatment of HHT related nosebleeds.
Phase:
Phase 2
Details
Lead Sponsor:
James Gossage
Collaborators:
Hereditary Hemorrhagic Telangiectasia Foundation International
HHT Foundation International
Treatments:
Bevacizumab
Endothelial Growth Factors
Estrogens
Tranexamic Acid